Scientists Struggling With Concerns Raised By Genome Project Progress

Genome Project Progress Some firms and institutions are establishing ethics branches to focus on policy issues left unresolved by NIH's ELSI project. RULES REQUIRED: Stanford's Paul Billings thinks ELSI has fallen short in creating a "regulatory arena". Many scientists are finding that concerns about the complex ethical, legal, and social issues surrounding genetic testing and the use of the resulting information are taking up a larger part of their time. In response to this shift in focus,

Written bySteven Benowitz
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Genome Project Progress Some firms and institutions are establishing ethics branches to focus on policy issues left unresolved by NIH's ELSI project.


RULES REQUIRED: Stanford's Paul Billings thinks ELSI has fallen short in creating a "regulatory arena".
Many scientists are finding that concerns about the complex ethical, legal, and social issues surrounding genetic testing and the use of the resulting information are taking up a larger part of their time.

In response to this shift in focus, and taking the conceptual lead from the Ethical, Legal, and Social Implications (ELSI) branch of the Human Genome Project (HGP), a growing number of biomedical institutions are organizing in-house committees and task forces to examine various ethical issues related to genetic testing and gene therapy. They are tackling a range of questions, from issues of genetic discrimination in jobs and insurance to informed consent, patients' right to know, rights to stored DNA and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies